Estabrook Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Estabrook Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14	Closed	-$488	–	406
2022 Q4	$488	Hold	14	–	–	﹤0.01%	412
2022 Q3	$783	Hold	14	–	–	﹤0.01%	400
2022 Q2	$725	Hold	14	–	–	﹤0.01%	410
2022 Q1	$1.02K	Hold	14	–	–	﹤0.01%	404
2021 Q4	$1.66K	Hold	14	–	–	﹤0.01%	420
2021 Q3	$1.88K	Hold	14	–	–	﹤0.01%	300
2021 Q2	$2.27K	Hold	14	–	–	﹤0.01%	297
2021 Q1	$1.12K	Hold	14	–	–	﹤0.01%	309
2020 Q4	$762	Hold	14	–	–	﹤0.01%	319
2020 Q3	$278	Hold	14	–	–	﹤0.01%	315
2020 Q2	$294	Hold	14	–	–	﹤0.01%	325
2020 Q1	$171	Hold	14	–	–	﹤0.01%	328
2019 Q4	$205	Buy	+14	New	+$195	﹤0.01%	335

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Estabrook Capital Management's NTLA Position: Q1 2023 in Review

Estabrook Capital Management sold out of Intellia Therapeutics (NTLA) in Q1 2023, closing a stake of 14 shares — an estimated $488 sold.

Estabrook Capital Management first reported a position in NTLA in Q4 2019 and held it in 13 quarters. The position peaked at $2.27K in Q2 2021. 290 funds tracked by Wall St. Rank hold NTLA as of Q1 2023.

Estabrook Capital Management reported no remaining Intellia Therapeutics position as of Q1 2023 after selling out during the quarter.
Estabrook Capital Management sold 14 Intellia Therapeutics shares in Q1 2023, an estimated $488.
Estabrook Capital Management first reported a position in Intellia Therapeutics in Q4 2019 and held it in 13 quarters.
Estabrook Capital Management's Intellia Therapeutics position peaked at $2.27K in Q2 2021.
290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2023.

Based on Estabrook Capital Management's 13F filing for Q1 2023, filed 12 May 2023.